|
|
Blood, 1 August 2007, Vol. 110, No. 3, pp. 847-850.
Prepublished online as a Blood First Edition Paper on April 5, 2007; DOI 10.1182/blood-2007-01-067546.
 Previous Article | Table of Contents | Next Article 
CLINICAL TRIALS AND OBSERVATIONS
Brief Report
CD4+CD25high Foxp3+ regulatory T cells in myelodysplastic syndrome (MDS)
Shahram Y. Kordasti1,
Wendy Ingram1,
Janet Hayden1,
David Darling1,
Linda Barber1,
Behdad Afzali2,
Giovanna Lombardi2,
Marcin W. Wlodarski3,
Jaroslaw P. Maciejewski3,
Farzin Farzaneh1, and
Ghulam J. Mufti1
1 Department of Hematological Medicine, King's College London, London, United Kingdom;
2 Immunoregulation Laboratory, Department of Nephrology and Transplantation, King's College London, London, United Kingdom;
3 Experimental Hematology and Hematopoiesis Section, Cleveland Clinic Foundation, Cleveland, OH.
Foxp3+ regulatory T cells (Tregs) play a central role in maintaining immune tolerance. A reduction in the function of Tregs is a key feature of autoimmune diseases, whereas their expansion in malignant diseases leads to the suppression of host antitumor responses. We analyzed the absolute number of CD4+ and CD8+ Tregs in the peripheral blood of 52 patients with myelodysplastic syndrome (MDS) and show a significant correlation between increased number of CD4+ Tregs and MDS subgroups with 5% or more bone marrow blasts (P < .001), high International Prognostic Scoring System (IPSS) score (P < .001), and disease progression (P < .001), whereas no correlation between CD8+ Tregs and prognostic variables was observed. The CD4+ Tregs showed a polyclonal spectratype, and the percentage of the naive subset was significantly higher in the high-risk patients compared with low-risk or healthy age-matched donors (P = .032). Our data suggest that CD4+ Treg expansion is a feature of high-risk MDS and progression to aggressive subtypes of the disease.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
I. Kotsianidis, E. Nakou, I. Bouchliou, A. Tzouvelekis, E. Spanoudakis, P. Steiropoulos, I. Sotiriou, V. Aidinis, D. Margaritis, C. Tsatalas, et al.
Global Impairment of CD4+CD25+FOXP3+ Regulatory T Cells in Idiopathic Pulmonary Fibrosis
Am. J. Respir. Crit. Care Med.,
June 15, 2009;
179(12):
1121 - 1130.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Mougiakakos, C. C. Johansson, and R. Kiessling
Naturally occurring regulatory T cells show reduced sensitivity toward oxidative stress-induced cell death
Blood,
April 9, 2009;
113(15):
3542 - 3545.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. J. Barrett and E. Sloand
Autoimmune mechanisms in the pathophysiology of myelodysplastic syndromes and their clinical relevance
Haematologica,
April 1, 2009;
94(4):
449 - 451.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. E.D. Chamuleau, T. M. Westers, L. van Dreunen, J. Groenland, A. Zevenbergen, C. M. Eeltink, G. J. Ossenkoppele, and A. A. van de Loosdrecht
Immune mediated autologous cytotoxicity against hematopoietic precursor cells in patients with myelodysplastic syndrome
Haematologica,
April 1, 2009;
94(4):
496 - 506.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Curti, S. Trabanelli, V. Salvestrini, M. Baccarani, and R. M. Lemoli
The role of indoleamine 2,3-dioxygenase in the induction of immune tolerance: focus on hematology
Blood,
March 12, 2009;
113(11):
2394 - 2401.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Mittal, N. A. Marshall, L. Duncan, D. J. Culligan, R. N. Barker, and M. A. Vickers
Local and systemic induction of CD4+CD25+ regulatory T-cell population by non-Hodgkin lymphoma
Blood,
June 1, 2008;
111(11):
5359 - 5370.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
X. Feng, S. Kajigaya, E. E. Solomou, K. Keyvanfar, X. Xu, N. Raghavachari, P. J. Munson, T. M. Herndon, J. Chen, and N. S. Young
Rabbit ATG but not horse ATG promotes expansion of functional CD4+CD25highFOXP3+ regulatory T cells in vitro
Blood,
April 1, 2008;
111(7):
3675 - 3683.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
